Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ona Therapeutics
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
The Barcelona-based firm, which has a protein splicing platform that aims to address the major limitation of delivering large genes using AAV vectors, has sealed the largest series A fundraising by a Spanish biotech.
Spain now enjoys a reasonable level of venture capital to help translate its scientific excellence into budding biotechs and the country's major life sciences backer Ysios is looking to unearth more jewels there, as well as in the rest of Europe and North America.
In this latest installment of VC Playbook, Chris Buyse – former chief financial officer of ThromboGenics – talks to In Vivo about the lessons he has learned from a career as a financial executive in the life sciences and his current venture, Fund+, a Belgian-based investment group focused on innovative companies primarily active in therapeutics R&D.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.